Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alpha plus chemotherapy as neoadjuvant therapy for resectable gastric and esophagogastric junction adenocarcinoma
ChiCTR2600124745Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- May 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in gastric adenocarcinoma and gastroesophageal adenocarcinoma, sponsored by Xijing Hospital. Primary endpoint: Pathological Complete Response Rate (pCR). Started May 2026; status: recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600124745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124745.